(19)
(11) EP 3 618 856 A1

(12)

(43) Date of publication:
11.03.2020 Bulletin 2020/11

(21) Application number: 18795120.7

(22) Date of filing: 30.04.2018
(51) International Patent Classification (IPC): 
A61K 39/00(2006.01)
A61P 35/00(2006.01)
A61K 39/02(2006.01)
C07H 21/02(2006.01)
(86) International application number:
PCT/US2018/030142
(87) International publication number:
WO 2018/204234 (08.11.2018 Gazette 2018/45)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 01.05.2017 US 201715583599

(71) Applicant: Morphogenesis, Inc.
Tampa, FL 33614 (US)

(72) Inventors:
  • LAWMAN, Michael, J. P.
    Temple Terrace, FL 33617 (US)
  • LAWMAN, Patricia, D.
    Temple Terrace, FL 33617 (US)
  • GENTILINI, Meghan
    Tampa, FL 33617 (US)
  • RAMIYA, Vijay
    Tampa, FL 33618 (US)
  • BASTAWROUS, Marina Victor, Abdelmaseeh
    Port Orange, FL 32128 (US)
  • SHAMBLOTT, Michael, J.
    St. Petersburg, FL 33605 (US)

(74) Representative: Zwicker, Jörk 
ZSP Patentanwälte PartG mbB Hansastraße 32
80686 München
80686 München (DE)

   


(54) MULTI-INDICATION MRNA CANCER IMMUNOTHERAPY